New cocktail of pills plus procedure aims to fight untreatable liver cancer

NCT ID NCT07309419

Not yet recruiting Disease control Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether combining a liver-directed procedure (TACE) with an oral triple-drug cocktail works better than TACE plus standard targeted therapy and immunotherapy for people with liver cancer that cannot be surgically removed. About 222 participants will be randomly assigned to one of the two treatment groups. The main goal is to see if the new combination helps people live longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Apatinib, Camrelizumab, Thalidomide, Capecitabine, and Compound cantharides capsule
What this could lead to: If successful, this could offer a new first-line treatment option for people with liver cancer that cannot be removed by surgery, potentially improving survival.
What could go wrong: This is an early-phase trial with only 222 participants, so results may not apply to everyone. The combination of multiple drugs may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.